Pemetrexed (Alimta®) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.

Original languageEnglish (US)
JournalClinical Breast Cancer
Volume3
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1 2002

Fingerprint

gemcitabine
Pemetrexed
Taxoids
Anthracyclines
Breast Neoplasms
Folic Acid Antagonists
Antimetabolites
Drug Combinations
Folic Acid
Neoplasms
Enzymes

Keywords

  • Anthracyclines
  • Gemcitabine
  • Multitargeted antifolate
  • Pemetrexed
  • Taxanes
  • Vitamin supplementation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{ed2eb72748824f7bb1a0667891a8510f,
title = "Pemetrexed (Alimta{\circledR}) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes",
abstract = "Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta{\circledR}) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.",
keywords = "Anthracyclines, Gemcitabine, Multitargeted antifolate, Pemetrexed, Taxanes, Vitamin supplementation",
author = "Alex Adjei",
year = "2002",
month = "1",
day = "1",
doi = "10.3816/CBC.2002.s.005",
language = "English (US)",
volume = "3",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Pemetrexed (Alimta®) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes

AU - Adjei, Alex

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.

AB - Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimidine antimetabolite with broad activity in a variety of solid tumors including breast cancer. Pemetrexed (Alimta®) is a novel, multitargeted antifolate that inhibits 3 folate-dependent enzymes, and is also broadly active in a wide variety of solid tumors. In breast cancer, pemetrexed has activity in patients previously treated with anthracyclines and taxanes, and pemetrexed demonstrates pre-clinical and clinical cytotoxic synergy with gemcitabine. This drug combination is being evaluated in a phase II study for the treatment of metastatic breast cancer patients who have previously received a taxane and an anthracycline.

KW - Anthracyclines

KW - Gemcitabine

KW - Multitargeted antifolate

KW - Pemetrexed

KW - Taxanes

KW - Vitamin supplementation

UR - http://www.scopus.com/inward/record.url?scp=0036072325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036072325&partnerID=8YFLogxK

U2 - 10.3816/CBC.2002.s.005

DO - 10.3816/CBC.2002.s.005

M3 - Article

C2 - 12057041

AN - SCOPUS:0036072325

VL - 3

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - SUPPL. 1

ER -